Kimia Biosciences Ltd announces an Extra-Ordinary General Meeting on July 22, 2025. Read full details, agenda, and shareholder information.
Kimia Biosciences Ltd Announces EGM on July 22, 2025
New Delhi, June 29, 2025 – Kimia Biosciences Ltd (BSE: 530313), a leading pharmaceutical and biosciences player, has formally informed the exchange as well as its shareholders regarding an impending Extra-Ordinary General Meeting (EGM) on Tuesday, July 22, 2025. Two filings by the company have been published through the Bombay Stock Exchange (BSE) approving the meeting as well as its agenda.
This EGM is particularly important to shareholders as the company wants to debate and approve important issues that will affect its strategic direction and corporate governance.
EGM Notification Details
As per the filings available on the BSE website, the announcement includes:
- Notice of the EGM along with detailed agenda items, attached as a PDF (24 pages)
- Intimation to Shareholders, outlining the date and objectives of the EGM
- Compliance with SEBI’s disclosure norms under Regulation 30 of LODR
The two relevant filings are titled:
- “NOTICE OF EXTRA-ORDINARY GENERAL MEETING SCHEDULED TO BE HELD ON 22 JULY, 2025”
- “INTIMATION OF EXTRA-ORDINARY GENERAL MEETING, SCHEDULED TO BE HELD ON 22 JULY 2025”
These filings are accessible to the public and interested investors via the BSE portal.
Key Agenda and Purpose
More Read
While the exact resolutions proposed for the meeting have not been fully disclosed in the summaries, such EGMs typically cover:
- Approval of new capital issuance (such as preferential allotments)
- Appointments or changes in directorship
- Business expansion decisions or strategic restructuring
- Ratification of past board decisions requiring shareholder consent
The detailed agenda is available in the PDF attachments submitted with the filings. Shareholders are advised to read these documents carefully and exercise their voting rights accordingly.
About Kimia Biosciences Ltd
Kimia Biosciences Ltd manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Kimia Biosciences Ltd has established itself as a contract development and manufacturing organization (CDMO), providing solutions to international pharmaceutical companies.
Through its dedication to quality, compliance with regulations, and innovation, Kimia Biosciences has become a trusted partner in the supply chain for healthcare.
Important Dates and Participation
- Date of EGM: July 22, 2025 (Tuesday)
- Mode: Likely via electronic means or physical presence, as specified in the notice
- Record Date / Cut-off Date: As per statutory norms (to be detailed in the full notice)
- e-Voting: Shareholders will be given the option to vote electronically in compliance with SEBI regulations
Investors holding shares as on the cut-off date will be eligible to participate and vote on the agenda items.
Market Relevance
Corporate decisions such as EGMs are an important point of contact between a firm and shareholders. Choices here can have lasting effects on shareholding composition, governance structures, and operational policies.
As Kimia Biosciences seeks to entrench its growth path in the biosciences sector, this EGM can serve as a launching pad for future initiatives.
Where to Access the Official Documents
Both filings are available in the company updates section of the BSE website. Direct links to the documents:
Shareholders and analysts are encouraged to review the official documents before forming conclusions or making investment decisions.
